双联抗血小板联合替罗非班对糖尿病急性心肌梗死的临床疗效和安全性分析  

Clinical Efficacy and Safety Analysis of Dual Antiplatelet Combined with Tirofiban on Diabetic Acute Myocardial Infarction

作　　者：王小科[1] WANG Xiaoke(Department of Cardiovascular Medicine,Fuling District Hospital of Traditional Chinese Medicine,Chongqing,408000 China)

机构地区：[1]重庆市涪陵区中医院心血管内科,重庆408000

出　　处：《系统医学》2022年第3期143-146,共4页Systems Medicine

摘　　要：目的研究双联抗血小板联合替罗非班对糖尿病急性心肌梗死患者的临床疗效及安全性。方法选择该院在2019年12月—2021年12月收治的160例糖尿病急性心肌梗死患者作为研究对象,按随机数字表法分成两组,各80例,对照组患者通过阿司匹林联合氯吡格雷进行治疗,观察组患者通过阿司匹林、氯吡格雷联合替罗非班进行治疗,比较两组患者临床治疗总有效率;治疗前后心功能指标[左房内径(LAd)、左室射血分数(LVEF)、左室舒张末径(LVDE)];治疗前后空腹血糖(PFG)与餐后2 h血糖(2 hPG);不良事件发生率(急性血栓、心绞痛、心肌梗死)。结果观察组患者临床治疗总有效率97.50%高于对照组82.50%,差异有统计学意义(χ^(2)=10.000,P<0.05);治疗后,观察组患者LAd、LVEF、LVDE均优于对照组患者,差异有统计学意义(P<0.05);治疗后,观察组患者PFG、2 hPG更低,差异有统计学意义(P<0.05);观察组患者不良事件发生更低,差异有统计学意义(P<0.05)。结论糖尿病急性心肌梗死患者通过双联抗血小板联合替罗非班进行治疗,能够有效提升临床疗效,改善血糖以及心功能,不良事件发生率低,具有较高安全性,值得推广。Objective To study the clinical efficacy and safety of dual antiplatelet combined with tirofiban in patients with diabetic acute myocardial infarction.Methods A total of 160 patients with diabetic acute myocardial infarction admitted to the hospital from December 2019 to December 2021 were selected as the study subjects.According to the random number table method,they were divided into two groups,with 80 patients in each group.The patients in the control group were treated with aspirin combined with clopidogrel,while the patients in the observation group were treated with aspirin,clopidogrel combined with tirofiban.The total effective rate of clinical treatment,cardiac function indexes[left atrial diameter(LAd),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVDE)]before and after treatment,fasting blood glucose(PFG)and postprandial blood glucose(2 hPG)before and after treatment;incidence of adverse events(acute thrombosis,angina,myocardial infarction)were compared between the two groups.Results The total effective rate of clinical treatment in the observation group was 97.50%higher than that in the control group 82.50%,the difference was statisicalhy significant(χ^(2)=10.000,P<0.05).After treatment,the LAd,LVEF and LVDE of the observation group were better than those of the control group,the difference was statisicalhy significant(P<0.05).After treatment,the PFG and 2 hPG in the observation group were lower,the difference was statisicalhy significant(P<0.05);the incidence of adverse events in the observation group was lower,the difference was statisicalhy significant(P<0.05).Conclusion Dual antiplatelet combined with tirofiban can effectively improve clinical efficacy,improve blood sugar and cardiac function in patients with diabetic acute myocardial infarction,and the incidence of adverse events is low.It has high security and is worthy of promotion.

关 键 词：双联抗血小板 替罗非班 糖尿病 急性心肌梗死 临床疗效 安全性 

分 类 号：R4[医药卫生—临床医学]